INTERACTIVE WORLD MAPClick a country to include or exclude it
IncludedExcludedHover
GLOBAL BUSINESS PLANGLOBAL BUSINESS PLANRosalind becomes a population-scale early-detection platform. Public systems create reach and evidence. Private channels create margin, service and speed. Paraguay remains the operating proof point.
Select countries, change the age envelope, set annual coverage, adjust prices and cost, and immediately see ten-year revenue and shareholder economics.
Price differentiation reflects setting, collection, navigation, laboratory hospitality and health concierge, not a different scientific test.
Population-scale access, contracted pathways, evidence and policy relevance.
Home, hotel or executive collection, human concierge and end-to-end navigation.
Premium partner laboratory, hybrid navigation and coordinated follow-up.
Accessible private pathway, digital-first delivery and protected escalation.
Launch timing, income tier, channel mix and territory multipliers remain country-specific.
| Region | Markets | Eligible women | Annual reach | 10Y revenue |
|---|
| Top territory | Launch | Eligible women | 10Y revenue |
|---|
Every input change updates annual tests, revenue, EBITDA, shareholder returns and funding need.
| Year | Tests (m) | Revenue | EBITDA | LiqSci | Partner |
|---|
Technology royalty, management fee and equity participation remain distinct.
Royalty for Rosalind intellectual property, method and brand.
Technical leadership, quality, transfer, training and continuous oversight.
LiqSci participates in after-tax territory profit through modeled equity.
The partner retains the non-LiqSci equity share across selected territories.
The model separates eligibility, annual coverage and completion of the downstream care pathway.
Selected countries + age envelope + under-42 eligible inclusion.
The editable percentage of total eligible women reached annually.
Actionable results require timely imaging, biopsy, diagnosis and treatment.
Stage shift and mortality reduction must be independently measured.
Quick access to related Rosalind and Sthorm platforms.
LiqSci is a pioneering biotechnology laboratory researching and developing liquid biopsy technologies.
Learn more